San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Cello Therapeutics is raising $20,051,713.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jie Zhang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cello Therapeutics
Cello is a biomedical company in San Diego, California, founded in 2016. Cello develops biomimetic cell membrane-coated nanoparticles for cancer drug delivery, including chemotherapy agents, immunotherapy agents, or mRNA. Our technology takes advantage of the properties of natural cellular membranes as a stealth coating for nanoparticles. Many animal studies indicated 85-100% of survival rate and long-term immunity for treating various solid tumors with the nanoparticles loaded with immunotherapy agent.

To learn more about Cello Therapeutics, visit http://cellotherapeutics.com/

Contact:
Jie Zhang, Chief Executive Officer
858-886-7649
https://www.linkedin.com/in/jie-zhang-72b87219a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved